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Bradykinin inhibits hepatic gluconeogenesis in
obese mice
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The kallikrein–kinin system (KKS) has been previously linked to glucose homeostasis. In isolated muscle or fat cells, acute
bradykinin (BK) stimulation was shown to improve insulin action and increase glucose uptake by promoting glucose
transporter 4 translocation to plasma membrane. However, the role for BK in the pathophysiology of obesity and type 2
diabetes remains largely unknown. To address this, we generated genetically obese mice (ob/ob) lacking the BK B2
receptor (obB2KO). Despite similar body weight or fat accumulation, obB2KO mice showed increased fasting glycemia
(162.3±28.2mg/dl vs 85.3±13.3mg/dl), hyperinsulinemia (7.71±1.75 ng/ml vs 4.09±0.51 ng/ml) and impaired glucose
tolerance when compared with ob/ob control mice (obWT), indicating insulin resistance and impaired glucose home-
ostasis. This was corroborated by increased glucose production in response to a pyruvate challenge. Increased gluco-
neogenesis was accompanied by increased hepatic mRNA expression of forkhead box protein O1 (FoxO1, four-fold),
peroxisome proliferator-activated receptor gamma co-activator 1-alpha (seven-fold), phosphoenolpyruvate carboxykinase
(PEPCK, three-fold) and glucose-6-phosphatase (eight-fold). FoxO1 nuclear exclusion was also impaired, as the obB2KO
mice showed increased levels of this transcription factor in the nucleus fraction of liver homogenates during random
feeding. Intraportal injection of BK in lean mice was able to decrease the hepatic mRNA expression of FoxO1 and PEPCK.
In conclusion, BK modulates glucose homeostasis by affecting hepatic glucose production in obWT. These results point to
a protective role of the KKS in the pathophysiology of type 2 diabetes mellitus.
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The pathophysiology of type 2 diabetes mellitus (T2DM)
involves innumerous metabolic and endocrine alterations,
including changes in the carbohydrate, lipid and protein
metabolisms. T2DM is directly linked with insulin resistance
and the inability of pancreatic beta cells to compensate for
these changes.1 There is also a strong association between
T2DM and obesity1,2 that persists independently of gender or
ethnic group. In this interaction, the weight gain of obese
subjects seems to precede the development of T2DM.3
Kinins are vasoactive peptides produced in the circulatory
system and other tissues by the action of serine proteases
called kallikreins. The kallikrein–kinin system (KKS) mod-
ulates pain, vasodilatation, vascular permeability, inflamma-
tion and edema and has been linked to insulin resistance.4–7
Bradykinin (BK), the agonist of the constitutively expressed
BK B2 receptor (BKB2R), has been reported to increase
glucose uptake in skeletal muscle and adipose tissue.8 At the
same time, the kinin B1 receptor and its agonist, the des-arg9-
kinin, have been shown to control leptin sensitivity7 and
insulin secretion.9
Despite evidence that acute BK stimulation improves
glucose uptake, the role for BK and BKB2R in the patho-
physiology of T2DM is still not clear. In isolated systems, it
has been shown that BK can trigger the translocation of the
glucose transporter 4 (GLUT4) in adipose tissue and muscle
either directly8 or by increasing insulin sensitivity.10–12
Miyata et al11 showed that BK can promote insulin action,
augmenting both the phosphorylation of the insulin receptor
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and the insulin receptor substrate-1 in skeletal muscle and rat
L6 myoblasts. Kishi et al8 concluded that BK increases
GLUT4 translocation in three different cell lines (L6
myotubes, 3T3-L1 adipocytes and CHO) independently on
insulin. The effect of BK on glucose uptake is nitric oxide
dependent, and thus absent in adipocytes of endothelial NO
synthase knockout mice.13 Furthermore, BK modulates the
feedback inhibition of insulin signaling at the level of insulin
receptor substrate-1.12 BK and nitric oxide are also involved
in the effects of leptin on glucose uptake.14
Patients treated with angiotensin-converting enzyme
inhibitors are less susceptible to develop T2DM.15
Angiotensin-converting enzyme has an important role not
only by converting angiotensin I to angiotensin II and
thereby increasing blood pressure, but also by inactivating
kinin peptides. This leads to an increase of kinin levels in
patients treated with angiotensin-converting enzyme
inhibitors,16–18 which has been proposed to protect these
patients against T2DM through a mechanism that has not
been completely elucidated.19
To study the involvement of BK in the pathophysiology of
T2DM in the context of obesity, the main etiological cause of
T2DM in humans, we studied obese ob/ob mice lacking
BKB2R (obB2KO). We were thus able to explore how the
deficiency of BKB2R influences glucose homeostasis of obese
mice (obWT). As liver is an important organ in the context of
T2DM, we were interested in the hepatic metabolism of these
animals.20 Despite remaining as obese as their ob/ob controls,
the obB2KO animals showed increased gluconeogenesis and
increased mRNA expression and nuclear accumulation of the
transcription factor forkhead box protein O1 (FoxO1). This
factor is known to control expression of the enzymes
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-
6-phosphatase (G6Pase) in the liver, both regulatory enzymes
of gluconeogenesis.21 Consistent with changes in FoxO1,
both PEPCK and G6Pase were increased in liver of obB2KO
mice. Conversely, intraportal injection of BK in lean mice
acutely decreased FoxO1 and PEPCK mRNA expression in
the liver. In this work we show, for the first time, that KKS is
strongly involved in glucose metabolism, not only acting in
peripheral glucose uptake as previously described but also by
affecting hepatic glucose production.
MATERIALS AND METHODS
Animals
Lepob/Lepob (ob/ob) and Bdkrb2tm/Bdkrb2tm mice, referred
to below as obWT and B2KO, respectively, all with the
C57BL/6J genetic background, were obtained from the
Center for the Development of Experimental Animal Models
(CEDEME), Federal University of Sa˜o Paulo (UNIFESP). The
infertility of obWT male mice was reverted using the white
adipose tissue transplantation technique.22 Transplanted
ob/ob males were mated with B2KO females to generate
Lepob.Bdkrb2tm/Lepob.Bdkrb2tm, referred below as obB2KO.
Mice were fed ad libitum with commercial rodent chow diet
(Nuvi Lab, Nuvital Parana´, Brazil) and neutral pH water, and
were maintained under a 12-h light/12-h dark cycle under
constant room temperature (22±1 1C) and humidity
(60±3%) conditions. The experiments were carried out
with females. All procedures complied with the standards for
the care and use of animals as stated in the guide for the care
and use of laboratory animals (UNIFESP).
Glycemic Analysis
All glycemic tests were performed on 3- and 6-month-old
mice. The glucose tolerance test and insulin tolerance test
were performed in animals fasted for 12 h. To avoid stress
there was an interval of 7 days between tests. Glycemia was
measured from blood drops from tails using a glucometer
(Accu-Chek Advantage). For the glucose tolerance test, 1 g
glucose and for the insulin tolerance test 1 IU of insulin were
i.p. injected per kg of body weight.
Serum Insulin Measurements
To measure serum insulin levels, blood samples were col-
lected at 10 am from 3-and 6-month-old mice, after 12 h of
fasting. The plasma was obtained by centrifugation at 2000 g
and frozen at  201C until use. The analyses were done with
a rat/mouse Insulin ELISA Kit (Millipore).
Morphometric Analysis
To determine the growth curve and the obesity development,
body weight was measured weekly until the mice reached the
age of 26 weeks. Thirty-week-old mice were killed and their
body weights as well as their organ weight were measured.
Liver pieces were saved in buffered formalin or frozen in liquid
nitrogen for further analysis. For histopathological analysis,
liver sections were stained with hematoxylin and eosin.
Body Composition
Total body fat was estimated in 25-week-old mice by dual-
energy X-ray absorptiometry using a Hologic QDR 4500
scanner (Hologic, Waltham, MA, USA) as described pre-
viously.23
Quantitative RT-PCR
Expression levels of different liver mRNAs were determined
by quantitative real-time PCR. Briefly, tissue explants from
12 h fasted mice were removed, snap frozen in liquid nitrogen
and stored at  80 1C until use. Samples were homogenized
and total RNA was isolated using a NucleoSpin RNA II
purification kit (Macherey-Nagel) and then stored at  80 1C
until use. The RNA integrity was assessed by electrophoresis
on agarose gels. cDNA was synthesized from 1 mg of total
RNA with Moloney murine leukemia virus reverse tran-
scriptase (Promega) using random hexamer nucleotides.
Standard curves for these molecules were made to determine
the amplification efficiencies of target and reference genes.
Quantitative PCR was performed on an ABI Prism 7900
sequence detection system using 100 nM of primers and
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5–20 ng of cDNA. Target mRNA expression was normalized
to b-actin and expressed as a relative value using the com-
parative threshold cycle (Ct) method (2DDCt) according to
the manufacturer’s instructions. Expression levels from genes
of interest were normalized to obWT control mice.
Nuclear Protein Extraction
For nuclear extraction, 200mg of fresh liver were homo-
genized with 0.8ml hypotonic buffer (final concentrations:
10mM HEPES-KOH, pH 7.9, 10mM KCl, 1.5mM MgCl2,
0.5mM DTT, 0.5% NP-40, 1mM PMSF and one tablet of the
Complete Inhibitor Cocktail (Roche) for each 25ml of buffer).
The homogenates were kept on ice for 20min. After mixing,
the samples were centrifuged at 2000 g, at 4 oC during 3min.
The cytoplasmic fractions were saved and the pellets re-
suspended in 180ml hypertonic buffer (final concentrations:
20mM HEPES-KOH, pH 7.9, 400mM NaCl, 1.5mM MgCl2,
0.5mM DTT, 0.2mM EDTA, 15% glycerol, 1mM PMSF and
one tablet of the Complete Inhibitor Cocktail (Roche) for each
25ml of buffer). After 30min incubation on ice, the samples
were centrifuged at 10 000 g, at 4 1C for 10min. The super-
natant containing the nuclear proteins were kept at  801C for
analyses of protein concentration and western blotting.
Western Blotting
Following the extraction procedure outlined above, the cy-
toplasmic and nuclear fractions were analyzed by western
blotting. After separation by SDS-PAGE, proteins were
transferred onto nitrocellulose membranes, which were
blocked with 5% milk for 1 h at room temperature. Mem-
branes were incubated overnight with primary antibodies
(FKHR—sc-11350, Santa Cruz), washed with tris-buffered
saline containing 0.1% Tween 20 and incubated with per-
oxidase-conjugated secondary antibodies for 1 h at room
temperature. Membranes were washed, incubated with Lu-
miGlochem iluminescence reagent and exposed on film.
Pyruvate Challenge
Twenty-four-hour food-deprived mice were i.p. injected with
sodium pyruvate (0.5 g/kg) for the pyruvate challenge test.
Blood samples were taken from the tail vein immediately
before and at various time points (30–240min) after the
pyruvate load.
Intraportal BK Injection
Lean wild-type C57BL/6J mice at the age of 3 months were
anesthetized with fluoretane. The body temperature was kept
constant by laying the mice onto a 37-1C-heating plate. The
abdominal cavity was opened and four bolus of 10 3M BK
or saline was injected into the portal vein each 5min totaling
100 ml of solution. After 30min, fragments of the liver were
collected and quickly frozen in liquid nitrogen until use for
RNA extraction.
Cell Culture
Rat hepatoma cells (FAO) were cultured in RPMI 1640
supplemented with 10% FBS. Insulin, cAMP (N6,20-O-di-
butyryladenosine 30,50-cyclic monophosphate sodium salt),
BK and HOE140 were purchased from Sigma (St Louis, MO,
USA). Groups were divided into 6 h fasting (without FBS)
and a fed state group, and tested with BK (10 6M) or
HOE140 (10 6M)þBK (10 6M) under three conditions:
control, with insulin (1 unit/l) or with cAMP (10 mM). The
cells were incubated during 3 h and the tRNA was extract
for quantitative RT-PCR analysis using the Invisorb Spin
Universal RNA Mini Kit (Invitek, Berlin, Germany).
Statistical Analysis
All values are expressed as mean±s.e.m. Statistical analyses
were carried out using the two-tailed Student’s unpaired t-
test to compare two independent groups or ANOVA followed
by Bonferroni’s test to compare more than two groups. Sig-
nificance was rejected at PZ0.05.
RESULTS
BKB2R Deficiency Potentiates Hyperglycemia and
Reduces Glucose Tolerance in obWT
The BKB2R has been shown to promote glucose uptake and
GLUT4 translocation in muscle and adipose tissue through a
insulin-dependent mechanism.10,11 In the absence of BKB2R,
mice showed normal insulin sensitivity but reduced glucose
tolerance (Figures 1a–f). Additionally, 6-month-old obB2KO
mice displayed a higher fasting hyperglycemia when com-
pared with obWT (162.3±28.2mg/dl vs 85.25±13.3mg/dl,
Figure 1g). Interestingly, this difference was observed only in
older mice. In fact, it has been shown that glucose metabo-
lism is improved in ob/ob mice at the age of 20 weeks,24–26
but this adaptation seems to be blunted in obB2KO mice. In
our experiments, we observed that 6-month-old obWT mice
showed lower glycemia than 3-month-old obWT mice
(Figure 1g). This correlates with a decrease in serum in-
sulin levels in these animals (Figure 1h), indicating that in-
creased insulin secretion is not the reason for the
improvement in basal glycemia.
BKB2R Deficiency Does not Affect Obesity or Fat
Accumulation in the ob/ob Model.
Deficiency of leptin in ob/ob mice causes severe obesity.
ObB2KO mice had similar body masses (60.55±3.94 vs
66.70±7.38; obWT vs obB2KO, respectively), similar growth
curves and similar body compositions (fat mass¼
68.80±2.97% vs 70.61±3.85%; lean mass 17.93±2.23% vs
20.61±3.66%, obWT vs obB2KO, respectively) than their
controls (Figure 2a–d). Body mass of the obB2KO mice was
higher during some weeks (18–25 weeks of age) but no sig-
nificant difference was found after 26 weeks (Figure 2a). It is
known that body fat distribution has a role in metabolism
and insulin sensitivity.27,28 Fat distribution in obB2KO mice
was similar to their controls when analyzed by dissection
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(Figure 2d). Moreover, the mass of spleen, pancreas, kidney,
skeletal muscle (gastrocnemius), heart and liver was not
different between the groups (Figures 2e and 4c).
The Gluconeogenesis Pathway is Upregulated in
obB2KO mice
In T2DM patients, increased gluconeogenesis was identified
as the main cause of fasting hyperglycemia.29 We thus
examined the main organ of gluconeogenesis, the liver, and
found that the expression of BKB2R mRNA was significantly
increased with age in obWT mice (2.44±0.48 fold, n¼ 6,
Figure 3a), coinciding with the improvement in glucose
metabolism. To test the gluconeogenesis pathway we used the
pyruvate challenge test to compare the capacity of obWT and
obB2KO mice to produce glucose from this substrate. The
test was carried out after 24 h of fasting and showed a more
prominent increase of glucose production in obB2KO mice
(Figure 3b), mainly 180 and 240min after the injection. This
increase in glucose production indicates increased gluco-
neogenesis in obB2KO mice, suggesting that BKB2R defi-
ciency can influence this pathway in obWT.
Expression of Gluconeogenesis Regulatory Enzymes is
Increased in obB2KO Mice
To assess the mechanism through which BKB2R deficiency
could modulate glucose production, we analyzed the
Figure 1 Reduction of basal glycemia and insulinemia in 6-month-old obese mice (obWT) mice. Glucose tolerance test (a–d) and insulin tolerance test
(e, f) in 3- and 6-month-old mice, n¼ 6; (g) fasting glycemia comparing 3- and 6-month-old mice, n¼ 6; (h) plasma insulin levels, n¼ 6. All tests were
carried out with the animals after 12 h of fasting. Values are presented as mean±s.e.m., n45, *Po0.05 and **Po0.01.
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expression level of mRNAs coding for enzymes and factors
involved in hepatic gluconeogenesis and found increased ex-
pression of G6Pase (eight-fold), PEPCK (three-fold), FoxO1
(four-fold) and peroxisome proliferator-activated receptor
gamma co-activator 1-alpha (PGC-1a, seven-fold) in liver of
obB2KO when compared with obWT (Figure 4a). G6Pase
and PEPCK are important regulatory enzymes for activation
of the gluconeogenesis pathway and both enzymes
are transcriptionally controlled by FoxO1.21 The 25-
hydroxycholesterol 7-alpha-hydroxylase (CYP7b1) expression
is dramatically decreased. Additionally, we found a decrease in
the expression of glucokinase (GCK) mRNA in obB2KO. This
enzyme is known to regulate the catabolism of glucose in
hepatocytes by phosphorylation of glucose to glucose-6-
phosphate.30 Other genes related to lipid metabolism in
the liver such as hepatocyte nuclear factor 4 alpha, 3-hydroxy-
3-methyl-glutaryl-CoA reductase, sterol regulatory element-
binding transcription factor 1, carnitine palmitoyltransferase-
1 and glycerol-3-phosphate acyltransferase were not different
in obB2KO mice in comparison with obWTmice (Figure 4a).
Consistent with the role of these enzymes in lipid metabolism,
liver histology showed no improvement of hepatic steatosis in
obB2KO when compared with obWTmice (Figure 4b). Liver
mass was also similar between obB2KO and obWT
(41.43±7.83mg/g vs 40.83±6.83mg/g body weight, respec-
tively; Figure 4c).
Expression and Cellular Distribution of FoxO1 Protein is
Affected in obB2KO Mice
The nuclear exclusion of FoxO1 is an important mechanism
to regulate glucose metabolism in the liver. Insulin can in-
hibit gluconeogenesis by Akt-mediated phosphorylation and
consequent nuclear exclusion of FoxO1.21 As a surrogate for
the amount of functional FoxO1 in the hepatic cells of obWT
Figure 2 Obesity and fat accumulation in obese mice lacking the bradykinin B2 receptor (obB2KO). (a) Body mass of obB2KO and obese mice (obWT)
mice up to 26 weeks of age; (b, c) body composition analyzed by densitometry in 23-week-old mice; (d) mass of fat depots obtained from 30-week-old
mice; SCAT, subcutaneous adipose tissue; GAT, gonadal adipose tissue; PAT, perirenal adipose tissue; and (e) mass of organs of 30-week-old mice,
gastrocnemius muscle (Gastroc). Values are presented as mean±s.e.m., n¼ 8, *Po0.05.
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and obB2KO mice, we performed western blot analysis of
nuclear extracts of random fed and 24 h fasted mice. These
analyses showed higher amounts of nuclear FoxO1 in the
liver of fed, but not fasted obB2KO mice when compared
with control mice (Figure 5).
BK Injection into the Portal Vein Acutely Decreases the
Expression of FoxO1 and PEPCK in Liver
To determine if BK could influence the expression of the
gluconeogenesis regulatory enzymes in vivo, wild-type mice
were anesthetized with isofluran and a bolus of BK was
injected into their portal vein. Mice were killed and liver
explants were collected 30min after the first bolus. Data
showed a significant decrease of the mRNA expression
of FoxO1 and PEPCK (37.3±14.3% and 49.1±19.2%,
respectively) when compared with controls (Figure 6). These
results therefore confirm that BK has an active role in the
regulation of gluconeogenesis.
BK Effect on the mRNA Expression of Gluconeogenesis
Factors in Hepatocytes Culture
To analyze whether the effect of BK in liver is due to the
direct action of BK on hepatocytes or if it is dependent on
other systems related with insulin sensitivity, we cultured rat
hepatoma cells (FAO) in different conditions, adding BK
alone or with the BKB2R antagonist HOE140. After 3 h, the
tRNA was extracted and quantitative RT-PCR analyses were
carried out. The cells reacted as expected to insulin or
cAMP, respectively, inhibiting or activating the expression of
both G6Pase and, PEPCK, when compared with the
control cells. FBS starved cells presented increased expression
of these factors keeping the same expression profiles in re-
spect to insulin or cAMP addition. BK (10 6M) could
slightly decrease the mRNA expression of PEPCK and FoxO1,
but not G6Pase in isolated FAO cells, and these effects were
observed only after FBS starvation and stimulation with
cAMP (Figure 7).
Figure 4 The expression of forkhead box protein O1 (FoxO1), phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) is
increased in the liver of obese mice lacking the bradykinin B2 receptor (obB2KO) mice. (a) Relative mRNA expression of enzymes involved in glucose
and lipid metabolism in the liver: FoxO1, glucokinase (GCK), G6Pase, PEPCK, 25-hydroxycholesterol 7-alpha-hydroxylase (CYP7b1), hepatocyte nuclear
factor 4 alpha (HNF4a), 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr), peroxisome proliferator-activated receptor gamma co-activator 1-alpha
(PGC-1a); cyclic AMP-responsive element-binding protein 1 (CREB), sterol regulatory element-binding protein 1 (SREBPf1); carnitine palmitoyltransferase-
1 (CPT1); acyl-CoA oxidase (ACO); glycerol-3-phosphate acyltransferase (GPAT); (b) representative microphotography of liver sections, stained with
hematoxylin and eosin, of the obese mice (obWT) and obB2KO mice, showing a similar pattern of steatosis; (c) liver mass of 30-week-old mice;
*Po0.05, **Po0.01, ***Po0.001, n¼ 5.
Figure 3 Increased expression of bradykinin B2 receptor (BKB2R) and
pyruvate challenge in 6-month-old mice. (a) BKB2R relative mRNA
expression of BKB2R mRNA in the liver of 3-and 6-month-old mice after
12 h fasting, n¼ 5. (b) Pyruvate tolerance curve performed in obWT
and obese mice lacking the bradykinin B2 receptor (obB2KO) mice
(6-month-old, 24 h starved, n¼ 5). Values are presented as mean±s.e.m.,
n45, *Po0.05 and **Po0.01.
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DISCUSSION
In order to study the participation of BK in the pathophy-
siology of obesity and T2DM, we generated a genetically
modified mouse deficient in leptin and the BKB2R. These
animals are as obese as their controls, which are deficient
only in leptin. On the other hand, obB2KO mice show higher
hyperglycemia and increased production of glucose during a
pyruvate challenge. Interestingly, these differences appear
only when the animals are 6 months old.
As the most important organ for gluconeogenesis is the
liver,31 we assessed the expression of BKB2R in the liver of
obWT animals of two different ages. As previously described
by several studies, the glycemia in obWT mice reduces
when animals are 6-month-old compared with younger
animals.24–26 Our results confirm this observation and demon-
strate that it coincides with an increase in BKB2R mRNA
expression in the liver of obWT mice with age, suggesting that
hepatic BKB2R might be involved in this process.
Although obB2KO mice do not show morphological
changes in liver, the mRNA expression of the most important
factors for activation of the gluconeogenesis was increased in
the liver of these animals compared with controls. FoxO1, an
important transcriptional factor to regulate gluconeogenesis
in liver,21 was increased at the mRNA level in the liver of
obB2KO mice. This result is consistent with the increase of
G6Pase and PEPCK mRNA expression observed in 6-month-
old obB2KO mice. The transcription factors and co-
activators involved in the control of gluconeogenesis have
been studied by several authors and confirmed by chromatin
immunoprecipitation assay.32–36 FoxO1 is also known to
inhibit the mRNA expression of CYP7A1.37 Consistently,
CYP7b1 expression is dramatically decreased in the liver of
obB2KO mice. These results together with increased glucose
production and higher hyperglycemia in obB2KO mice point
to a chronic upregulation of the gluconeogenesis pathway in
obB2KO mice.
One way of regulating the activity of FoxO1 is by the
phosphorylation and subsequent nuclear exclusion of this
factor in the cell.38 The protein kinase B (AKT) is the main
kinase responsible for nuclear exclusion of FoxO1.39
Under conditions of abundant glucose, ie, during fed state,
insulin is released and promotes activation of AKT in the
liver with subsequent FoxO1 phosphorylation and nuclear
exclusion.40,41 It then results in inhibition of expression of
enzymes responsible for gluconeogenesis.42 Under random
fed regimen, obB2KO mice exhibit an atypical increase in
Figure 5 Changes in the regulation of the nuclear exclusion of the
forkhead box protein O1 (FoxO1). Analysis and representative image of
western blots of nuclear and cytoplasmic fractions of the liver of
obBKB2R mice and controls, either random fed or 24 h starved, n¼ 4,
RF¼ random fed, 24¼ 24 h starved. Values are presented as
meanþ s.e.m., *Po0.05.
Figure 6 Effects of portal injection of bradykinin (BK) in anesthetized WT
lean mice. Relative mRNA expression of enzymes involved in glucose
metabolism in the liver after 30min of intraportal BK bolus injection; n¼ 4:
forkhead box protein O1 (FoxO1), glucose-6-phosphatase (G6Pase),
phosphoenolpyruvate carboxykinase (PEPCK) and glucokinase (GCK). Values
are presented as mean±s.e.m. of relative changes of mRNA levels when
compared with the controls, *Po0.05, **Po0.01 relative to control.
Bradykinin and gluconeogenesis
CC Barros et al
www.laboratoryinvestigation.org | Laboratory Investigation | Volume 92 October 2012 1425
nuclear FoxO1 levels. Interestingly, these levels are similar to
the levels observed in fasted mice, which suggest that: (1)
obB2KO are not responsive to insulin or other signals that
inhibit gluconeogenesis in response to feeding; and (2)
independently on the feeding status, nuclear FoxO1 is at its
maximum levels in obB2KO mice. Thus, the increase in
fasting gluconeogenesis should be related to the higher
expression of PGC-1a in obB2KO, as it was reported that this
co-activator is responsible for activation/stabilization of the
transcriptional complex necessary for the transcriptional
activity of FoxO1.43 Furthermore, PGC-1a has also been
associated with metabolic changes in the liver, especially with
the activation of gluconeogenesis.43
All these results are in consonance with Hartl et al,44 who
proposed that the favorable effects of systemic administration
of kinins in humans could be mediated by prostaglandins. On
the other hand, diet induced liver-insulin-resistance in rats was
followed by decreased plasma BK level in a metabolomic
analysis45 suggesting that the insulin pathway could be involved
in metabolic effect of BK in vivo. Although it is unclear whether
the mechanism is insulin dependent or not, the present work
shows that the KKS is involved in this process.
We also tested the effect of BK in cultured hepatoma cells.
In this isolated system, BK had only a slight effect to inhibit
PEPCK and FoxO1 expression, but none regarding G6Pase.
This effect was blocked by previous incubation with the
BKB2R antagonist HOE140. These results are similar to those
observed after BK injection in the portal vein in vivo
(Figure 6), suggesting that the chronic effects of BK in
obB2KO mice are also dependent on other systems as suggest
by Li et al,45 who showed a cross talking between the KKS
and the insulin pathway,45 and other several studies that
show the influence of BK in insulin secretion of the
pancreatic cells.46–49 It is important to highlight that this
finding was only observed in cells that were FBS starved
during 6 h and were also stimulated with cAMP, the second
messenger of the glucagon receptor pathway.
The model of obesity used in the present work was im-
portant to demonstrate the effect of BK in hepatic gluco-
neogenesis. Duka et al5 showed that the lean B2KO mice have
significantly higher steady-state insulin levels, significantly
lower glucose uptake rates and insulin sensitivity indexes, but
did not analyze hepatic gluconeogenesis. We challenged these
lean mice with the pyruvate tolerance test (Supplementary
Figure S1) and we also carried out hepatic mRNA expression
analysis of some gluconeogenesis factors (FoxO1, G6Pase,
PEPCK and PGC-1; Supplementary Figure S2). The analyses
did not show differences in gluconeogenesis activity or in
expression of these factors in the lean B2KO mice when
compared with the lean WT controls, as presented in the
supplementary data.
In summary, these results show that the BKB2R partici-
pates in the regulation of hepatic glucose production of
obWT, but not in lean mice. This scenario takes place with an
increase in the expression and a decrease in the nuclear ex-
clusion of FoxO1 and consequent increase in the expression
of PEPCK and G6Pase mRNAs. Increased activity of FoxO1
in obB2KO during fasting is also promoted by increased
PGC-1a. It points to a protective effect of BK and its analogs
in obese, T2DM individuals.
Supplementary Information accompanies the paper on the Laboratory
Investigation website (http://www.laboratoryinvestigation.org)
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Figure 7 Effect of bradykinin (BK) in cultured hepatome cells (FAO). The cells were distributed in two groups: with or without fetal bovine serum
(þ FBS or  FBS). Three different conditions were used concerning absence or addition of insulin and cAMP. Each condition was tested with or
without BK (10 6M) and HOE140 (10 6M), a BKB2R antagonist. Values are presented as mean±s.e.m., *Po0.05, n¼ 3.
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